Literature DB >> 8404856

Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function.

B Stein1, A S Baldwin, D W Ballard, W C Greene, P Angel, P Herrlich.   

Abstract

NF-kappa B and AP-1 represent distinct mammalian transcription factors that target unique DNA enhancer elements. The heterodimeric NF-kappa B complex is typically composed of two DNA binding subunits, NF-kappa B p50 and NF-kappa B p65, which share structural homology with the c-rel proto-oncogene product. Similarly, the AP-1 transcription factor complex is comprised of dimers of the c-fos and c-jun proto-oncogene products or of closely related proteins. We now demonstrate that the bZIP regions of c-Fos and c-Jun are capable of physically interacting with NF-kappa B p65 through the Rel homology domain. This complex of NF-kappa B p65 and Jun or Fos exhibits enhanced DNA binding and biological function via both the kappa B and AP-1 response elements including synergistic activation of the 5' long terminal repeat of the human immunodeficiency virus type 1. These findings support a combinatorial mechanism of gene regulation involving the unexpected cross-coupling of two different classes of transcription factors to form novel protein complexes exhibiting potentiated biological activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8404856      PMCID: PMC413671          DOI: 10.1002/j.1460-2075.1993.tb06066.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  104 in total

Review 1.  Fos and Jun: the AP-1 connection.

Authors:  T Curran; B R Franza
Journal:  Cell       Date:  1988-11-04       Impact factor: 41.582

2.  The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1.

Authors:  P Angel; K Hattori; T Smeal; M Karin
Journal:  Cell       Date:  1988-12-02       Impact factor: 41.582

3.  The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins.

Authors:  W H Landschulz; P F Johnson; S L McKnight
Journal:  Science       Date:  1988-06-24       Impact factor: 47.728

4.  The role of the leucine zipper in the fos-jun interaction.

Authors:  T Kouzarides; E Ziff
Journal:  Nature       Date:  1988-12-15       Impact factor: 49.962

5.  New procedure for DNA transfection with polycation and dimethyl sulfoxide.

Authors:  S Kawai; M Nishizawa
Journal:  Mol Cell Biol       Date:  1984-06       Impact factor: 4.272

6.  Requirement for fos gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol esters.

Authors:  A Schönthal; P Herrlich; H J Rahmsdorf; H Ponta
Journal:  Cell       Date:  1988-07-29       Impact factor: 41.582

7.  The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes.

Authors:  R Chiu; W J Boyle; J Meek; T Smeal; T Hunter; M Karin
Journal:  Cell       Date:  1988-08-12       Impact factor: 41.582

8.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

9.  I kappa B: a specific inhibitor of the NF-kappa B transcription factor.

Authors:  P A Baeuerle; D Baltimore
Journal:  Science       Date:  1988-10-28       Impact factor: 47.728

10.  Induction of proto-oncogene JUN/AP-1 by serum and TPA.

Authors:  W W Lamph; P Wamsley; P Sassone-Corsi; I M Verma
Journal:  Nature       Date:  1988-08-18       Impact factor: 49.962

View more
  153 in total

1.  NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1.

Authors:  D C Guttridge; C Albanese; J Y Reuther; R G Pestell; A S Baldwin
Journal:  Mol Cell Biol       Date:  1999-08       Impact factor: 4.272

Review 2.  NF-kappaB and apoptosis in mammary epithelial cells.

Authors:  R W Clarkson; C J Watson
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-04       Impact factor: 2.673

3.  Reciprocal interaction between two cellular proteins, Puralpha and YB-1, modulates transcriptional activity of JCVCY in glial cells.

Authors:  M Safak; G L Gallia; K Khalili
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

4.  Repression of transforming-growth-factor-beta-mediated transcription by nuclear factor kappaB.

Authors:  R P Nagarajan; F Chen; W Li; E Vig; M A Harrington; H Nakshatri; Y Chen
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

5.  Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-κB activity.

Authors:  Frank Wolschendorf; Alberto Bosque; Takao Shishido; Alexandra Duverger; Jennifer Jones; Vicente Planelles; Olaf Kutsch
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

Review 6.  The role of AP-1, NF-kappaB and ROS/NOS in skin carcinogenesis: the JB6 model is predictive.

Authors:  Arindam Dhar; Mathew R Young; Nancy H Colburn
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

7.  Inhibition by pentoxifylline of TNF-alpha-stimulated fractalkine production in vascular smooth muscle cells: evidence for mediation by NF-kappa B down-regulation.

Authors:  Yung-Ming Chen; Chao-Jung Tu; Kung-Yu Hung; Kwan-Dun Wu; Tun-Jun Tsai; Bor-Shen Hsieh
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

8.  Tumor necrosis factor alpha induction of NF-kappaB requires the novel coactivator SIMPL.

Authors:  Hyung-Joo Kwon; Erin Haag Breese; Eva Vig-Varga; Yong Luo; Younghee Lee; Mark G Goebl; Maureen A Harrington
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

9.  Effect of CD28 signal transduction on c-Rel in human peripheral blood T cells.

Authors:  R G Bryan; Y Li; J H Lai; M Van; N R Rice; R R Rich; T H Tan
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

10.  The C-terminal domain of c-fos is required for activation of an AP-1 site specific for jun-fos heterodimers.

Authors:  K McBride; M Nemer
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.